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Sir Alexander Haddow discovered the first chemical therapy
to treat cancer [1]. Based on Paul Ehrlich’s pioneering work
that resulted in chemical therapy or chemotherapy to treat
bacterial infections [2], Haddow investigated the therapeutic
potential of numerous polycyclic hydrocarbons to cause
tumour regression in experimental animals. Some compounds
were effective, but the fact that they were known carcinogens
prohibited further exploration in humans. Nevertheless, the
triphenylethylene-based oestrogens [3] have a structural
similarity to polycyclic hydrocarbons and they were also
observed to cause tumour regression in animals. This was the
translational basis of Haddow’s landmark clinical experiments
to evaluate the efficacy of high-dose oestrogen on the growth
of breast and prostate cancer. Responses were noted but
Haddow later commented [4] in 1970 during the inaugural
David A Karnofsky lecture that, ‘The extraordinary extent of
tumour regression observed in perhaps 1% of postmenopausal
cases has always been regarded as of major theoretical
importance and it is a matter of some disappointment that so
much of the underlying mechanisms continue to elude us.’
High-dose oestrogen therapy was introduced into clinical care
during the 1950s [5] for the treatment of postmenopausal
women with metastatic breast cancer. This approach
complemented the use of ovarian ablation (using radiation at
that time) in premenopausal patients, but the observation that
high-dose oestrogen was an effective treatment for one in
three elderly postmenopausal breast cancer patients remained
a mechanistic paradox until recently [6].
Through serendipity, a young endocrinologist, Leonard Lerner
at Merrell Dowe Pharmaceuticals in the USA, recognized that
a triphenylethanolic compound being tested as a cardio-
vascular drug had a structure similar to the triphenylethylenes
[7]. He asked to test the compound but found that there was
no oestrogenic activity in any species tested, only anti-
oestrogen activity. The compound, MER25 or ethamoxy-
triphetol, was the first nonsteroidal anti-oestrogen [8].
However, it was the fact that nonsteroidal anti-oestrogens
were postcoital antifertility agents in rats that drove the
structural evolution of triphenylethylene-based oestrogens to
become a whole range of novel anti-oestrogenic compounds
[9]. Regrettably, the promise of preventing pregnancy was
premature because the compounds actually induced
ovulation [10]. Also, drug toxicities noted during the 1960s
and 1970s retarded any serious consideration of the non-
steroidal anti-oestrogens as therapeutic agents for indica-
tions such as breast cancer therapy [10]. Only ICI 46,474,
the trans isomer of a substituted triphenylethylene [11], took
a tenuous path to clinical testing in breast cancer [10,12] and
was subsequently kept on life support to be reinvented [13]
as a potential targeted therapy for the long-term adjuvant
treatment and prevention for oestrogen receptor positive
breast cancer.
Today, the advance with the clinical implementation of the
scientific strategy is profound [14,15], and the practice of
oncology has progressed significantly over the past three
decades [6]. However, the consequences of long-term
antihormonal therapy is drug resistance, and it is the
laboratory study of the drug resistance of tamoxifen and
subsequently the aromatase inhibitors that has provided the
opportunity to solve the paradox of high-dose oestrogen
therapy in breast cancer. Solving this mystery has had the
potential to show the way forward for future advances in
cancer care.
Models to study the development of drug resistance to long-
term tamoxifen resistance were first reported 20 years ago
[16,17]. Drug resistance to tamoxifen develops within about a
year in MCF-7 breast cancer cells. Inoculated cells grow into
transplantable tamoxifen-stimulated tumours in ovariectomized
athymic mice [16], and drug resistance (subsequently also
noted for raloxifene [18,19]) is consistent with clinical
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experience. However, it should be stressed that tamoxifen-
stimulated growth is a unique form of drug resistance.
Tumours stop growing when tamoxifen is withdrawn, but
oestrogen also stimulates tumours to grow. This is the
scientific basis for the use of an aromatase inhibitor or
fulvestrant, the pure anti-oestrogen, after the development of
tamoxifen resistance [20]. However, the finding that tamoxifen
resistance actually evolves into new phases [21] provided an
experimental basis for solving the mystery of the mechanism
of high-dose oestrogen therapy and an opportunity to
enhance the effectiveness of antihormonal therapy in patients
rendered refractory to multiple anti-oestrogenic treatments.
Tamoxifen-stimulated MCF-7 breast tumours can only be
maintained as a model of human disease by serial trans-
plantation into tamoxifen-treated athymic mice; no appropriate
cellular model is available. However, the realization that the
model does not replicate adjuvant treatment with tamoxifen (5
or more years) raised the question of what occurs under
these clinical circumstances. The discovery that physiological
oestrogen causes rapid tumour regression of long-term (5
plus years) tamoxifen-resistant MCF-7 tumours [22] and the
subsequent finding that the oestrogen-stimulated regrowth of
regressed tumour would again respond to the anti-oestrogen
tamoxifen [23] indicated a new strategic approach to cancer
care. Simply stated, for the first time there was a novel
method for killing antihormone-resistant breast cancer cells
and then effectively retreating with tamoxifen to maintain
responding patients for longer periods. The development of
mechanistic studies and the important observations that the
principle of oestrogen-stimulated tumour cell regression and
apoptosis also applied to oestrogen-deprived cells
(aromatase inhibitor resistant) [24-26] enhanced the overall
relevance of the observations and provided opportunities for
further mechanism based clinical trials.
The important study conducted by Lønning and coworkers
[27] provides the laboratory-to-clinic translation of the fact
that high-dose oestrogen treatment can produce a response
rate of up to 30% among patients who have been treated
with exhaustive antihormone therapy. The question now being
addressed in multiple clinical studies is whether low-dose
oestrogen therapy will be as effective in treating patients with
a sensitized breast tumour.
With the evolution of thinking about oestrogen action
following Haddow’s success with the first chemical therapy
[1], it is reasonable to examine how we can improve the
efficacy of long-term antihormonal therapy and the putative
30% response rate of low-dose oestrogen therapy in
metastatic breast cancer. We are pursuing two paths. To
improve long-term antihormone therapy, we are investigating
the value of long-term vascular endothelial growth factor
receptor (VEGFR)2 inhibitors [28] to block residual oestrogen
or selective oestrogen receptor modulator induced VEGF
secretion [29]. The recent report that VEGF creates drug
resistance to tamoxifen [30] implies that dual long-term
adjuvant treatment with tamoxifen and a VEFGR2 inhibitor will
have potential clinical merit. However, the key to success, we
believe, is the use of low-dose VEGFR2 inhibitor with the
adjuvant antihormone to avoid toxicity during long-term therapy.
To improve the value of low-dose oestrogen therapy
treatment after exhaustive antihormonal therapy, we believe
that the real question is why do 70% of tumours in the clinic
not respond to oestrogen induced apoptosis? We have
developed cell lines that either respond rapidly or have a
delayed response to oestrogen. Using this approach, we
have examined the inhibitor of glutathione synthesis buthio-
nine sulfoximine, which has previously been evaluated in the
clinic to improve responses to chemotherapy [31]. In prelimi-
nary studies, buthionine sulfoximine dramatically enhanced
the response of refractory antihormone resistant cells to the
early apoptotic actions of oestrogen.
We suggest that there is now a clinical opportunity to use our
proposed clinical trial [6,32] design that employs a yet to be
determined 12-week course of low-dose oestradiol therapy to
treat patients after exhaustive antihormonal therapy. A
succession of combined antisurvival agents could potentially
improve response rates to well above the 30% rate in
metastatic breast cancer rendered refractory by exhaustive
antihormonal therapy. The novel test platform is rapid and has
tumour response as the end-point. We believe that new
combinations of agents could subsequently be employed in
much larger trials without oestrogen once its apoptotic
efficacy is established.
In closing, it is gratifying that the story of oestrogen action
through the oestrogen receptor has continued to offer
surprises in each decade since Haddow’s report in 1944 [1].
By looking back, we have been able to plan a way forward to
benefit patients.
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